Financial Performance - The company's operating revenue for Q3 2023 was ¥58,283,821.52, a decrease of 85.55% compared to the same period last year, and a decline of 89.10% year-to-date[5]. - The net profit attributable to shareholders for Q3 2023 was ¥3,021,706.56, down 97.99% year-on-year, with a year-to-date decline of 94.49%[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥1,190,472.83, a decrease of 99.18% compared to the previous year, and a decline of 95.98% year-to-date[5]. - The basic earnings per share for Q3 2023 was ¥0.02, down 97.47% year-on-year, with a year-to-date decline of 94.51%[6]. - Total operating revenue for the first three quarters of 2023 was CNY 205,201,872.85, a significant decrease from CNY 1,882,802,710.96 in the same period of 2022, representing a decline of approximately 89.1%[19]. - Net profit for the third quarter of 2023 was CNY 34,641,306.81, a decrease of approximately 94.5% compared to CNY 628,349,515.82 in the same quarter of 2022[20]. - The total equity attributable to shareholders was CNY 3,996,173,217.40, compared to CNY 4,200,411,657.40 in the previous year, showing a decrease of approximately 4.8%[18]. - The total comprehensive income for the third quarter of 2023 was CNY 25,136,286.38, down from CNY 614,364,651.67 in the same quarter of 2022, reflecting a decrease of about 95.9%[21]. Research and Development - The total R&D investment for Q3 2023 was ¥14,084,477.39, a decrease of 38.22% compared to the same period last year, and a year-to-date decline of 22.76%[6]. - R&D investment accounted for 24.17% of operating revenue in Q3 2023, an increase of 18.52 percentage points year-on-year[6]. - Research and development expenses for the first three quarters of 2023 were CNY 42,353,979.69, down from CNY 54,836,951.31 in the same period of 2022, indicating a reduction of about 22.7%[19]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,223,766,266.75, a decrease of 10.96% compared to the end of the previous year[6]. - The equity attributable to shareholders at the end of the reporting period was ¥3,996,173,217.40, down 4.86% year-on-year[6]. - The company's current assets totaled ¥3,401,779,972.87, down from ¥3,909,848,957.27, indicating a decrease of about 13%[16]. - The total liabilities of the company as of the third quarter of 2023 amounted to CNY 227,593,049.35, down from CNY 543,439,647.94 in the previous year, reflecting a reduction of about 58.1%[20]. - The total liabilities of the company were not explicitly stated, but accounts payable decreased significantly to ¥109,137,010.53 from ¥317,670,146.75, a reduction of about 65.6%[16]. - The company reported a significant drop in contract liabilities from ¥59,317,687.74 to ¥22,785,391.43, representing a decrease of approximately 61.6%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was negative, primarily due to a significant decline in sales revenue[10]. - Operating cash flow for the first nine months was negative at -145,253,368.09, compared to a positive cash flow of 473,382,062.50 in the same period last year[25]. - Total cash inflow from operating activities was 356,878,605.48, while cash outflow was 502,131,973.57, resulting in a net cash flow from operating activities of -145,253,368.09[25]. - Investment activities generated a net cash flow of -42,307,352.79, with cash inflow of 7,215,805.63 and outflow of 49,523,158.42[26]. - Financing activities resulted in a net cash flow of -233,158,750.37, with cash outflow for debt repayment and dividend distribution totaling 233,158,750.37[26]. - The cash and cash equivalents at the end of the period decreased to 2,758,032,313.85 from 3,147,723,751.88 at the beginning of the period[26]. Market and Demand - The company experienced a substantial decrease in demand for COVID-related business, impacting overall sales revenue and profitability[10]. - The company has not disclosed any new product developments or market expansion strategies in the current report[15].

证券代码：688317 证券简称：之江生物 公告编号：2023-026 上海之江生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 09 月 05 日(星期二) 至 09 月 11 日(星期一)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@liferiver.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 上海之江生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 29 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 09 月 12 日 上午 09:00- 10:0 ...

海通证券股份有限公司 经中国证券监督管理委员会《关于同意上海之江生物科技股份有限公司首次 公开发行股票注册的批复》（[2020]3214 号）核准，上海之江生物科技股份有限 公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股票 4,867.6088 万股，每股面值人民币 1 元，每股发行价格人民币 43.22 元，募集资金总额为 人民币 210,378.0523 万元，扣除发行费用后，实际募集资金净额为人民币 194,232.1639 万元。本次发行证券已于 2021 年 1 月 18 日在上海证券交易所 上市。海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其 持续督导保荐机构，持续督导期间为 2021 年 1 月 18 日至 2024 年 12 月 31 日。 在 2021 年 1 月 18 日至 2024 年 12 月 31 日持续督导期内（以下简称"本持 续督导期间"），保荐机构及保荐代表人按照《证券发行上市保荐业务管理办法》 1 （以下简称"保荐办法"）、《上海证券交易所科创板股票上市规则》等相关规 定，通过日常沟通、定期回访、现场检查、尽职调查等方式进行持续督导，现就 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a total revenue of ¥XX million, representing a YY% growth compared to the same period last year[16]. - The company's operating revenue for the first half of 2023 was ¥146,918,051.33, a decrease of 90.07% compared to the same period last year[21]. - Net profit attributable to shareholders was ¥31,619,600.25, down 93.38% year-on-year[21]. - The net profit after deducting non-recurring gains and losses decreased by 95.00% to ¥23,838,539.17[21]. - The net cash flow from operating activities fell by 156.52% to -¥177,592,184.96, primarily due to a significant drop in sales revenue[22]. - Basic and diluted earnings per share were both ¥0.17, a decline of 93.06% compared to the previous year[21]. - The company achieved a revenue of 146.92 million yuan in the reporting period, a year-on-year decrease of 90.07%[65]. - The net profit attributable to shareholders was 31.62 million yuan, down 93.38% year-on-year, primarily due to a reduction in sales volume of COVID-related products[65]. Research and Development - Research and development expenses increased by FF%, reflecting the company's commitment to innovation and new technology[16]. - The R&D investment as a percentage of operating revenue increased to 19.24%, up 17.08 percentage points year-on-year[21]. - The total R&D investment for the reporting period was ¥28,269,502.30, a decrease of 11.76% compared to ¥32,038,652.78 in the same period last year[49]. - The number of R&D personnel increased to 156, representing 39.49% of the total workforce, up from 35.21% in the previous year[55]. - The total compensation for R&D personnel reached RMB 1.32461 million, with an average salary of RMB 8.49 million, compared to RMB 1.04667 million and RMB 7.27 million respectively in the previous year[55]. - The company has developed over 400 products across 20 major series in molecular diagnostic reagents and instruments, making it one of the most comprehensive in the field of infectious disease diagnostics in China[28]. - The company has developed multiple patented technologies for the preparation of nano magnetic beads, enabling the extraction of nucleic acids from various pathogens, thus breaking the monopoly of Western manufacturers and achieving import substitution[37]. Market Expansion and Strategy - The company is expanding its market presence in international regions, targeting a growth rate of DD% in overseas markets by the end of 2023[16]. - The company has completed a strategic acquisition of a complementary business, which is anticipated to contribute an additional ¥EE million in revenue annually[16]. - The company is actively participating in various industry conferences to enhance market promotion and expand market channels[67]. - The company is expanding its overseas market presence through established branches in the US and Singapore[67]. Product Development and Innovation - New product development includes the launch of a novel diagnostic tool, expected to enhance market competitiveness and drive sales growth[16]. - The company has developed a fully automated nucleic acid detection platform with an expected total investment of ¥6,000,000, with ¥419,020 invested in the current period[52]. - The company has launched mobile P2+ nucleic acid testing vehicles, such as "Red Armor" and "Blue Armor," which can perform nucleic acid testing on-site, reducing sample transport risks and time[38]. - The company has established a comprehensive product line in the respiratory field, including tests for COVID-19, H1N1, and other respiratory pathogens, holding over 10 Class III registration certificates[36]. Regulatory and Compliance - The company has identified key risks in its operations, including regulatory changes and market competition, and has outlined strategies to mitigate these risks[4]. - The company maintains a strong governance structure, ensuring transparency and accountability in its financial reporting[5]. - The company has established a comprehensive quality management system and has received ISO13485 certification to ensure product quality[60]. Environmental Responsibility - The company has implemented strict measures for wastewater treatment, ensuring compliance with environmental regulations[97]. - The company emphasizes the importance of environmental responsibility and has taken steps to contribute to green initiatives[100]. - The company has established a mechanism for environmental protection and is classified as a key pollutant discharge unit[96]. Shareholder Commitments and Governance - The company has committed to protecting investor interests, especially those of minority shareholders, through effective fundraising management[144]. - The company will ensure that any share reduction after the lock-up period will not be below the IPO price and will disclose control arrangements[115]. - The commitments made by the controlling shareholder are irrevocable during their control period[110]. - The company will retain any gains from share transfers if the actual controller violates the commitments, and may withhold payments until compliance is met[118]. Financial Position and Assets - As of June 30, 2023, the company's total assets amounted to CNY 4,278,165,823.70, a decrease from CNY 4,743,851,305.34 at the end of 2022[196]. - The company's total liabilities were CNY 279,515,980.95, down from CNY 543,439,647.94 in the previous period[197]. - The cash and cash equivalents decreased to CNY 2,743,867,354.38 from CNY 3,147,723,751.88[195]. - Accounts receivable decreased to CNY 162,694,703.85 from CNY 227,622,831.28[195].

独立董事关于第五届董事会第二次会议相关事项 的独立意见 根据《公司法》、《上海之江生物科技股份有限公司章程》等相关规定,我们 作为上海之江生物科技股份有限公司(以下简称"公司")的独立董事,基于独 立判断的立场,本着实事求是的原则,对公司下列事项进行了认真的核查,现就 公司第五届董事会第二次会议审议的相关事项发表独立意见如下: 上海之江生物科技股份有限公司 独立董事(签字): 于永生 2023 年 8 月 27 日 (本页无正文，为上海之江生物科技股份有限公司独立董事关于第五届董事 会第二次会议相关事项的独立意见签署页) 独立董事（签字): 李学尧: 一.《关于公司 2023年半年度募集资金存放与实际使用情况的专项报告的 议案》的独立意见 我们认为:公司2023年半年度募集资金的存放和使用符合中国证券监督管 理委员会、上海证券交易所关于上市公司募集资金存放和使用的相关规定,不存 在违规使用募集资金的行为,不存在改变或变相改变募集资金投向和损害股东利 益的情况,公司所披露的募集资金存放和使用情况信息与实际情况一致,如实履 行了信息披露义务。我们同意《关于公司 2023年半年度募集资金存放与实际使 用情况的专项报 ...

证券代码：688317 证券简称：之江生物 公告编号：2023-024 上海之江生物科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 截至 2023 年 6 月 30 日止，本年度使用募集资金 19,573.70 万元，结余募 集资金(含利息收入扣除银行手续费的净额)余额为 29,145.58 万元。具体情况如 下： | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》、 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》及有 关规定，上海之江生物科技股份有限公司（以下简称"公司"）董事会编制了 2023 年半年度募集资金存放与实际使用情况的专项报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 根据中国证券监督管理委员会于 2020 年 11 月 27 日出具的证监许可 [2020]3214 号文《关于同意上海之江生物科技股份有限公司首次公开发行股票 注册的批复》，公司获准向社会公 ...

上海之江生物科技股份有限公司 第五届监事会第二次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688317 证券简称：之江生物 公告编号：2023-025 表决结果：3 票同意、0 票反对、0 票弃权、0 票回避。 监事会认为：公司 2023 年半年度报告全文及摘要内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或重大遗漏；公司 2023 年半年度报告全文及 摘要的编制和审议程序符合相关法律法规和《公司章程》等内部规章制度的规定， 公允地反映了公司 2023 年半年度的财务状况和经营成果等事项；半年度报告编 制过程中，未发现公司参与半年度报告编制和审议的人员有违反保密规定的行为。 2、审议通过《关于公司 2023 年半年度募集资金存放与实际使用情况的专项 报告的议案》 表决结果：3 票同意、0 票反对、0 票弃权、0 票回避。 监事会认为：公司 2023 年半年度募集资金存放与使用情况符合《上海证券 交易所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥84,348,212.48, a decrease of 89.59% compared to the same period last year[5] - Net profit attributable to shareholders was ¥6,026,571.66, down 97.81% year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥7,015,965.17, reflecting a decline of 97.45% compared to the previous year[5] - The net cash flow from operating activities was -¥171,882,022.73, a decrease of 162.34% year-on-year[6] - Basic and diluted earnings per share were both ¥0.03, down 97.87% from the same period last year[6] - The total comprehensive income for Q1 2023 was ¥3,658,041.80, a decrease from ¥267,248,470.93 in Q1 2022, reflecting a decline of approximately 98.6%[20] - The total operating profit for Q1 2023 was ¥10,063,921.65, a significant drop from ¥324,239,329.48 in Q1 2022, reflecting a decline of about 96.9%[23] Research and Development - Research and development expenses totaled ¥14,504,728.20, an increase of 30.34% compared to the previous year[6] - R&D expenses accounted for 17.20% of operating revenue, up 15.83 percentage points year-on-year[6] - Research and development expenses increased to ¥14,504,728.20 in Q1 2023 from ¥11,128,219.98 in Q1 2022, marking an increase of about 30.7%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,524,640,294.07, a decrease of 4.62% from the end of the previous year[6] - Cash and cash equivalents as of March 31, 2023, were RMB 2,923,264,994.00, down from RMB 3,147,723,751.88 at the end of 2022, showing a decrease of approximately 7.1%[14] - Accounts receivable decreased to RMB 204,565,453.68 from RMB 227,622,831.28, a decline of about 10.1%[14] - Inventory increased to RMB 516,133,617.18 from RMB 504,032,006.81, representing a growth of approximately 2.2%[14] - Total liabilities decreased to RMB 320,570,594.87 from RMB 543,439,647.94, a reduction of approximately 41.0%[16] - Shareholders' equity attributable to shareholders was ¥4,204,069,699.20, a slight increase of 0.09% compared to the previous year[6] - Shareholders' equity increased slightly to RMB 4,204,069,699.20 from RMB 4,200,411,657.40, reflecting a marginal growth[16] Business Strategy and Outlook - The company reported a significant decline in sales revenue due to changes in product sales structure[8] - The company reported a significant drop in both revenue and operating costs, indicating potential restructuring or changes in business strategy[18] - The company has not provided specific guidance for future performance or new product developments in this report[12] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was -¥171,882,022.73, compared to ¥275,709,142.52 in Q1 2022, representing a decline of approximately 162.3%[23] - The company reported a net cash outflow from investing activities of -¥42,034,813.73 in Q1 2023, compared to -¥43,788,254.52 in Q1 2022, showing a slight improvement[24] - Cash and cash equivalents at the end of Q1 2023 were ¥2,923,264,994.00, down from ¥3,164,464,365.60 at the end of Q1 2022, indicating a decrease of approximately 7.6%[24] Foreign Exchange Impact - The company experienced a foreign exchange loss of -¥10,541,921.43 in Q1 2023, compared to -¥3,381,492.57 in Q1 2022, indicating a worsening of approximately 211.5%[24]

Financial Performance - The net profit attributable to shareholders for 2022 was RMB 760,273,479.93, with a total distributable profit of RMB 1,717,459,254.86 as of December 31, 2022[6]. - The company plans to distribute a cash dividend of RMB 12 per 10 shares, totaling RMB 230,589,598.80 (including tax) based on the total share capital of 194,704,350 shares[6]. - The total cash dividend for the year amounted to RMB 332,623,516.07, representing 43.75% of the net profit attributable to shareholders[7]. - The company's operating revenue for 2022 was CNY 2,326,255,117.23, representing a 15.23% increase compared to CNY 2,018,829,748.78 in 2021[24]. - The net profit attributable to shareholders of the listed company for 2022 was CNY 760,273,479.93, a slight increase of 0.23% from CNY 758,524,934.06 in 2021[24]. - The net profit after deducting non-recurring gains and losses was CNY 712,091,183.01, down 3.23% from CNY 735,871,022.81 in 2021[24]. - The company's total assets at the end of 2022 were CNY 4,743,851,305.34, an increase of 11.50% from CNY 4,254,679,653.54 at the end of 2021[24]. - The weighted average return on net assets for 2022 was 19.00%, a decrease of 3.13 percentage points from 22.13% in 2021[25]. - The basic earnings per share for 2022 were CNY 3.93, a decrease of 1.26% from CNY 3.98 in 2021[25]. - The net cash flow from operating activities for 2022 was CNY 584,971,135.46, a decrease of 8.87% from CNY 641,937,293.08 in 2021[24]. Share Repurchase and Dividends - The company has repurchased shares with a total expenditure of RMB 102,033,917.27 as of December 31, 2022[7]. - The company has not implemented any other forms of profit distribution, such as capital reserve transfers or stock dividends, for the current year[7]. - The total cash dividends distributed in 2022 amounted to RMB 332,623,516.07, including the amount for share repurchases[195]. Research and Development - Research and development expenses accounted for 4.50% of operating revenue in 2022, down from 5.39% in 2021[26]. - The company has developed over 400 products in molecular diagnostic reagents and instruments, making it one of the most comprehensive providers of infectious disease molecular diagnostic products in China[43]. - The company has established a comprehensive R&D platform and has developed core technologies such as automated nucleic acid extraction and multiplex real-time PCR technology[88]. - The company has ongoing projects in the respiratory pathogen detection field, with a total investment of ¥8,000,000, of which ¥3,986,670 was invested this period, achieving CE certification for four products[75]. - The company has a strong focus on R&D, with a total of 14 new applications and 6 patents granted during the reporting period[69]. Market and Product Development - The global in vitro diagnostic (IVD) market is projected to reach $127.4 billion in 2022, with expectations to grow to approximately $140 billion by 2027, driven by emerging markets like China and India[50]. - The molecular diagnostics sector is the fastest-growing sub-industry within IVD, with applications in infectious diseases, tumor diagnosis, and genetic disease diagnosis[50]. - The company aims to enhance its product offerings by developing new diagnostic kits, including blood screening nucleic acid test kits and tumor early screening gene test kits[142]. - The company is focusing on expanding its product offerings in high-risk virus detection, with ongoing development of automated extraction reagents and devices[79]. Operational Risks and Management - The company has outlined various operational risks and corresponding mitigation measures in the report[5]. - The company faces risks related to core technology leakage, new product development, and market competition, which could impact its competitive edge[96]. - The company emphasizes the importance of retaining high-quality technical talent to maintain its technological leadership and core competitiveness[98]. - The company is exposed to risks of intensified market competition and potential price declines for its diagnostic products due to increasing market entrants and regulatory changes[99]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[9]. - The company has established a compensation and assessment committee to evaluate and determine the compensation plans for senior management based on their specific roles[198]. Employee and Talent Development - The company employed a total of 435 staff, with 166 in technical roles and 132 in sales[185]. - The total number of R&D personnel increased to 166, accounting for 38.16% of the total workforce, up from 35.59% in the previous year[85]. - The total compensation for R&D personnel reached approximately 23.3 million RMB, with an average salary of 140,350 RMB[85]. - The company emphasizes talent development and has implemented multi-dimensional training programs for employees[188]. Future Outlook - The company provided a forward guidance of 1.5 billion in revenue for the next fiscal year, indicating a growth target of 25%[166]. - New product launches are expected to contribute an additional 200 million in revenue by the end of the year[167]. - The company aims to achieve international recognition for its product quality through enhanced media promotion and participation in influential projects[142]. - The company plans to strengthen its talent development and employee motivation strategies, focusing on high-level talent recruitment and internal training systems to support business growth and technological innovation[144].

证券代码：688317 证券简称：之江生物 公告编号：2023-008 上海之江生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 04 月 27 日(星期四) 上午 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （一）会议召开时间：2023 年 04 月 27 日上午 09:00-10:00 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事长：邵俊斌先生 投资者可于 2023 年 04 月 20 日(星期四) 至 04 月 26 日(星期三)16:00 前 登录上证路演中心网站 ...